Oxaplain 100 Injection contains Oxaliplatin 100mg, a platinum-based chemotherapy agent indicated for the treatment of colorectal cancer, gastric cancer, and other solid tumors. It helps in inhibiting cancer cell growth, preventing tumor progression, and improving patient outcomes.
Oxaliplatin works by forming DNA cross-links in rapidly dividing cancer cells, disrupting replication and transcription, and inducing apoptosis. Its intravenous injection allows precise dosing and effective systemic delivery in oncology settings.
For distributors and healthcare suppliers, Oxaplain 100 Injection is a high-demand anticancer therapy product, widely used in hospitals, oncology centers, and chemotherapy clinics. The growing prevalence of colorectal and solid tumors ensures steady and long-term market demand.
Adding Oxaplain 100 Injection to your oncology therapy segment creates strong opportunities in hospitals, cancer care centers, export markets, and third-party manufacturing. Its proven efficacy, platinum-based formulation, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.